Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced the acceptance of four abstracts for the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place from October 23-25, 2024, in Barcelona, Spain. The…
Siemens Healthineers is collaborating with over 20 industry and public partners, including seven leading stroke hospitals, to enhance stroke management across Europe. The five-year UMBRELLA project, with a total budget of €26.9 million, is partly funded by the Innovative Health…
HCA Healthcare, Inc. (NYSE: HCA), a leading healthcare provider in the U.S., has announced a $1 million donation to support Hurricane Helene relief efforts in North Carolina through community organizations. On September 26, Hurricane Helene made landfall as a powerful…
Aetna®, a CVS Health® company, has announced its 2025 Medicare products, focusing on essential benefits that enhance members’ overall health. The offerings include affordable Medicare Advantage (MA) plans featuring $0 monthly premiums, $0 copays for primary care visits, and $0…
Elevance Health (NYSE: ELV) has announced its affiliated health plans will offer flexible Medicare Advantage options with personalized supplemental benefits aimed at enhancing the overall health of nearly 40.3 million Medicare-eligible consumers across 23 states and Puerto Rico. These plans…
UnitedHealthcare has announced a $335,000 funding initiative aimed at enhancing healthcare access in Idaho, particularly for underserved communities, including rural populations, individuals with chronic conditions, and seniors. “By expanding programs for caregivers, community health workers, and healthcare providers, we can…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that it presented data demonstrating the effectiveness of sebetralstat in reducing anxiety during hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) in Copenhagen, Denmark, on October 4-5, 2024. This data, derived…
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on innovative treatments for neurological diseases, announced the granting of inducement awards to three new employees. The Board’s Compensation Committee approved the issuance of non-qualified stock options to purchase a…
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology firm focused on developing innovative small molecules for immune-mediated diseases, has announced that its Investigational New Drug (IND) application for zetomipzomib, aimed at treating lupus nephritis (LN), has been placed on…
TheraVectys, a biotechnology firm focused on creating lentiviral vector-based vaccines and immunotherapies for infectious diseases and cancers, has announced the enrollment of the first patient in a Phase I/IIa clinical trial for its onco-therapeutic vaccine, Lenti-HPV-07. This trial aims to…
